Results 81 to 90 of about 5,652 (210)

Lichen Planus Following COVID‐19 Infection and Vaccination. Matched Case–Control Study

open access: yesAustralasian Journal of Dermatology, Volume 66, Issue 5, Page 289-295, August 2025.
ABSTRACT Background New‐onset lichen planus (LP) development following COVID‐19 infection/vaccination is reported. Since case series cannot be used to study exposure–outcome associations, we designed this matched case–control study to investigate whether COVID‐19‐related events and de novo LP are associated.
Paolo Giacomo Arduino   +4 more
wiley   +1 more source

Childhood pemphigus

open access: yesIndian Journal of Dermatology, 2006
Childhood pemphigus is a rare diasease and comprises only a minority of immunobullous diseases seen in children. Almost all variants of pemphigus in childhood have been described in literature.
De Dipankar, Kanwar Amrinder
doaj  

Safety and Efficacy of a Neonatal Fc Receptor Antagonist in Patients With Anti‐NMDAR Encephalitis

open access: yesCNS Neuroscience &Therapeutics, Volume 31, Issue 8, August 2025.
Efgartigimod reduces IgG recycling and promotes the degradation of IgG and pathogenic autoantibodies. Efgartigimod treatment for anti‐NMDA receptor encephalitis was associated with no apparent adverse effects and accelerated improvements in neurological dysfunction and clinical symptoms, particularly cognitive function.
Zhihong Bian   +8 more
wiley   +1 more source

Dermatology [PDF]

open access: yes, 2004
Dermatology continues to develop at a steady pace. In the past few years there have been exciting advances in our understanding of skin structure and function in health and disease and progress in genetics, epidemiology, immunology, pharmacology and ...
Boffa, Michael J.
core   +1 more source

Analysis of human leukocyte antigen genotypes in pemphigus with antidesmoglein antibody profile shift

open access: yesDermatologica Sinica, 2016
In particular pemphigus cases, the phenotypic transition between pemphigus vulgaris and pemphigus foliaceus is observed with the change of antibody profile between anti-desmoglein (Dsg) 3 antibodies and anti-Dsg1 antibodies.
Seiko Mitsui   +4 more
doaj   +1 more source

Primary cutaneous CD8‐positive aggressive epidermotropic cytotoxic T‐cell lymphoma initially demonstrating near‐complete metabolic response to BV‐CHEP

open access: yes
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume 23, Issue 10, Page 1308-1311, October 2025.
Tristen Tze Wei Ng   +5 more
wiley   +1 more source

CTLA4 CT60 gene polymorphism is not associated with differential susceptibility to pemphigus foliaceus

open access: yesGenetics and Molecular Biology, 2010
Pemphigus foliaceus is an organ-specific autoimmune disease characterized by autoantibodies against the extracellular region of desmoglein 1, a protein that mediates intercellular adhesion in desmosomes.
Márcia Regina Pincerati   +2 more
doaj  

Different signaling patterns contribute to loss of keratinocyte cohesion dependent on autoantibody profile in pemphigus

open access: yesScientific Reports, 2017
Pemphigus is an autoimmune blistering skin disease caused primarily by autoantibodies against desmoglein (Dsg)1 and 3. Here, we characterized the mechanisms engaged by pemphigus IgG from patients with different clinical phenotypes and autoantibody ...
Elias Walter   +10 more
doaj   +1 more source

Primäres kutanes CD8‐positives aggressives epidermotropes zytotoxisches T‐Zell‐Lymphom mit anfänglich nahezu vollständigem metabolischem Ansprechen auf BV‐CHEP

open access: yes
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume 23, Issue 10, Page 1308-1311, October 2025.
Tristen Tze Wei Ng   +5 more
wiley   +1 more source

Tumour necrosis factor-α polymorphism as one of the complex inherited factors in pemphigus

open access: yesMediators of Inflammation, 2003
The aim of our study was to analyse a significance of tumour necrosis factor (TNF)-α promoter gene polymorphisms in relation to the HLA-DR locus in genetic predisposition to pemphigus.
Jolanta Dorota Torzecka   +6 more
doaj   +1 more source

Home - About - Disclaimer - Privacy